Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers (ADUL-SSc)
Regional Grafting of Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers: a Prospective Randomized Controlled Study
A randomized controlled trial will be performed to confirm preliminary uncontrolled data indicating that regional adipose tissue grafting is effective in inducing digital ulcer healing in patients with systemic sclerosis.
Systemic Sclerosis patients with digital ulcers will be randomized to be blindly treated with adipose tissue implantation or a sham procedure. Adipose tissue grafting will consist of injection at the base of the finger with digital ulcer of 0.5-1 ml of adipose tissue after centrifugation of fat aspirate. Sharm procedure will consist of false liposuction and local injection of saline solution.
The primary end-point will be to compare the cumulative prevalence of healed digital ulcers in the two groups within the following 8 weeks.
調査の概要
詳細な説明
Systemic sclerosis (SSc) is an autoimmune disease characterized by a multifactorial pathological process where a central role is played by the progressive loss of the microvascular bed, with the consequent fibrotic changes in the involved organs and tissues.
The most advanced stages of capillary loss may induce the formation of digital ulcers (DUs) on the fingertips.The healing of DUs is often a lengthy process requiring accurate and intensive topical and systemic treatment. Nevertheless, in a significant number of cases this therapeutic approach is ineffective and distal necrosis with subsequent tissue loss or phalangeal amputation may eventually occur.
In a recent open pilot study performed by Del Papa et al., it has been demonstrated that autologous adipose tissue grafting (AT-G), which is known to contain both adipose-derived stem cells and a stromal/vascular fraction, was effective in inducing prompt healing of long lasting DUs localized in the fingertips of a small number of patients with SSc. The DU healing was accompanied by the rapid disappearance of local ischemic pain and evidence of a partial restoration of the capillary bed in the digits when assessed by nailfold videocapillaroscopy (NVC).
With the purpose of confirming these preliminary results, the investigators have designed a monocentric randomized controlled study. In accordance with the study protocol, patients with a typical SSc-related DU on the fingertip will be randomized to undergo a regional AT-G with autologous fat as active therapy or a 'sham' procedure (SP) - that simulates the active treatment - as placebo treatment. All of the patients with SSc enrolled in both arms will be blind regarding the treatment received. Furthermore, during the study period all of the enrolled patients will receive the same systemic vasoactive and topical therapy.
研究の種類
入学 (予想される)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Milan、イタリア、20122
- 募集
- UOC Day Hospital Reumatologia, ASST G. Pini-CTO
-
コンタクト:
- Nicoletta Del Papa, MD
- 電話番号:+39-0258296415
- メール:nicoletta.delpapa@asst-pini-cto.it
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients candidate for enrollment in the study have to meet the 2013 classification criteria of the American College of Rheumatology/European League Against Rheumatism for SSc;
- Patients may have either the limited cutaneous or the diffuse cutaneous variants of SSc;
- All of the candidate patients must have only one active DU (cardinal ulcer), lasting for at least 6 weeks prior to enrolment time and showing no tendency to heal despite intravenous iloprost (0.5-2 ng/Kg/min), the oral administration of calcium-channel blockers (nifedipine) and local medication with surgical removal of necrotic tissue.
Exclusion Criteria:
- Presence of severe extra-cutaneous manifestations, such as cardiac, lung and renal involvement;
- Concomitant treatment with immune-suppressive therapies (including prednisone equivalent >10 mg);
- Current therapy with dual and selective endothelin inhibitors;
- Concomitant diabetes and/or other vascular diseases;
- Current pregnancy or breastfeeding.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Autologous fat grafting
Implantation of 0.5-1 ml of autologous AT at the base of the finger with DU.
|
Implantation of small amount of autologous adipose tissue at the base of the finger to induce a rapid healing of the distally located DU
他の名前:
|
|
プラセボコンパレーター:Sham procedure
False liposuction followed by the injection of 0.5-1 ml of 0.9% saline solution at the base of the affected finger.
|
Local injection of 0.5ml saline solution after a simulated liposuction procedure.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Digital Ulcer healing
時間枠:8 weeks after either autologus fat grafting or sham procedure.
|
Prevalence of DU healing in the arm treated with autologous fat grafting in comparison with the prevalence of healing in the placebo group.
|
8 weeks after either autologus fat grafting or sham procedure.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pain evaluation by Visual Analogue Scale (VAS)
時間枠:This evaluation will be done at baseline and at the 2nd, 4th, 6th, 8th week after interventions (either autologus fat grafting or sham procedure).
|
The pain VAS is a continuous scale comprised of a horizontal line of 10 centimeters (100 mm) in length, ranging from 0 (minimum= no pain) to 100 (worst imaginable pain). The respondents will be asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. In this study VAS score will be used to measure the decrease (or resolution) of pain with respect to baseline value in patients who will undergo treatment with autologous fat grafting (active arm) in comparison with patients of the placebo group. |
This evaluation will be done at baseline and at the 2nd, 4th, 6th, 8th week after interventions (either autologus fat grafting or sham procedure).
|
|
Neovascularization evaluation
時間枠:Baseline and 8 weeks after either autologus fat grafting or sham procedure.
|
Increase of the number of capillaries assessed by NVC in the affected digit of patients treated with autologous fat grafting in comparison with patients of the placebo group.
|
Baseline and 8 weeks after either autologus fat grafting or sham procedure.
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Nicoletta Del Papa, MD、ASST Gaetano Pini-CTO
出版物と役立つリンク
一般刊行物
- Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009 May 7;360(19):1989-2003. doi: 10.1056/NEJMra0806188. No abstract available.
- Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii19-24. doi: 10.1093/rheumatology/kep105.
- Del Papa N, Di Luca G, Sambataro D, Zaccara E, Maglione W, Gabrielli A, Fraticelli P, Moroncini G, Beretta L, Santaniello A, Sambataro G, Ferraresi R, Vitali C. Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis. Cell Transplant. 2015;24(11):2297-305. doi: 10.3727/096368914X685636. Epub 2014 Dec 12.
- Del Papa N, Di Luca G, Andracco R, Zaccara E, Maglione W, Pignataro F, Minniti A, Vitali C. Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study. Arthritis Res Ther. 2019 Jan 7;21(1):7. doi: 10.1186/s13075-018-1792-8.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- ID Sperimentazione 138
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Autologous fat graftingの臨床試験
-
NYU Langone HealthNational Institute on Deafness and Other Communication Disorders (NIDCD)募集
-
Washington University School of MedicineAbbVie終了しました
-
Centre Hospitalier Universitaire de la Réunion完了
-
Fred Hutchinson Cancer CenterJuno Therapeutics, Inc., a Bristol-Myers Squibb Company終了しました難治性B細胞非ホジキンリンパ腫 | 再発性成人急性リンパ芽球性白血病 | 再発性B細胞非ホジキンリンパ腫 | 再発びまん性大細胞型B細胞リンパ腫 | 再発原発性縦隔(胸腺)大細胞型B細胞リンパ腫 | 難治性成人急性リンパ芽球性白血病 | 難治性びまん性大細胞型B細胞リンパ腫 | 難治性原発縦隔(胸腺)大細胞型B細胞リンパ腫 | 再発性形質転換非ホジキンリンパ腫 | MYC、BCL2、および BCL6 再構成を伴う再発高悪性度 B 細胞性リンパ腫 | MYC、BCL2、および BCL6 再構成を伴う難治性高悪性度 B 細胞性リンパ腫 | 再発B型急性リンパ芽球性白血病 | 特に明記されていない再発性びまん性大細胞型B細胞性リンパ腫 | MYCおよ... およびその他の条件アメリカ
-
City of Hope Medical CenterBristol-Myers Squibb; National Cancer Institute (NCI); Gateway for Cancer Research積極的、募集していない